Intraoperative electron radiation therapy after salvage surgery in gynecological cancers and retroperitoneal sarcomas: outcomes and adverse effects

BackgroundSalvage surgery is considered an option for isolated recurrences of retroperitoneal and pelvic tumors, in patients who have undergone previous radiotherapy. In order to increase local control intra operative electron radiation therapy (IOERT) can be used in these patients to administer additional radiation dose. We evaluated the outcomes and adverse effects in patients with retroperitoneal sarcoma and gynecologic tumors after salvage surgery and IOERT.Materials and methodsTwenty patients were retrospectively analyzed. Twenty-three IOERT treatments were performed after surgery. Six (30%) were sarcoma and 14 (70%) were gynecological carcinoma. Administered dose depended on previous dose received with external beam radiotherapy (EBRT) and proximity to critical structures. The toxicities were scored using the Common Terminology Criteria for Adverse Events version 4.0.ResultsThe median age of the patients was 51 years (range 34–70). After a median follow-up of 32 months (range 1–68), in the sarcoma group the local control rate was 66.6%; while in the gynecological group the local control rate was 64.3%. In relation to late toxicity, one patient had a Grade 2 vesicovaginal fistula, and one patient presented Grade 4 enterocolitis and enteric intestinal fistula.ConclusionsIOERT could have a role in the treatment of retroperitoneal sarcomas in primary tumors after EBRT, as it may suggest a benefit in local control or recurrences after surgical resection in those at high risk of microscopic residual disease. The addition of IOERT to salvage resection for isolated recurrence of gynecologic cancers suggest favorable local control in cases with concern for residual microscopic disease.     

MiRNA介导circRNA调控肿瘤的发展

CircRNA(circular RNA)是一种具有特殊环形结构的ncRNA(non-coding RNA),并具有多种生物学功能.随着研究的深入,发现circRNA能够通过海绵吸附抑制miRNA(micro RNA)的表达,进而调控各系统肿瘤的发展.此外,一种circRNA也可参与调控一种或多种miRNA的表达,这一...     

Stem-like cells in human hepatoblastoma.

Hepatoblastoma is a pediatric liver tumor with epithelial components resembling embryonal and fetal liver cells. The existence of teratoid hepatoblastoma suggests the presence of stem cells in hepatoblastoma. The aim of this study was to analyze the expression of stem cell markers in hepatoblastomas. We studied specimens from 10 hepatoblastomas. Five of the hepatoblastomas were of epithelial and five of mixed type. Immunohistochemistry (IHC) for the stem cell markers CD34, Thy1, c-kit, and the hepatic or biliary lineage markers CK-18, OCH, CK-7, and CD56 was performed. Double IHC for stem cell and lineage markers was used to identify putative liver stem cells. The different markers showed distinct distributions on the tumor cells. Cells in atypical ducts were found to express simultaneously stem cell markers and hepatocytic or biliary lineage markers. Other cells in connective tissue showed c-kit expression, but not hepatic or biliary marker expression. The data show the presence of different cell populations bearing stem cell markers in human hepatoblastoma. Ductal cells co-expressing stem cell markers and hepatic lineage markers phenotypically resemble hepatic stem-like cells. These findings support the thesis that stem cells play a role in the histogenesis of hepatoblastoma.     

肿瘤浸润淋巴细胞在实体肿瘤中作用的研究进展

肿瘤是21世纪威胁人类健康的主要疾患之一。临床上,实体瘤治疗仍以手术切除、放化疗和靶向治疗为主,但这些方法往往不能根除肿瘤病灶,易导致肿瘤复发和进展。肿瘤免疫治疗是利用人体的免疫系统,通过增强或恢复抗肿瘤免疫力实现控制和杀伤肿瘤的一种新的治疗模式。肿瘤免疫治疗能够在众多患者中产生持久反应,过继性免疫治疗和免疫检查点阻断剂治疗均可产生显著的抗原特异性免疫反应。肿瘤浸润淋巴细胞(TILs)是一种存在于肿瘤组织内部具有高度异质性的淋巴细胞,在宿主抗原特异性肿瘤免疫应答中发挥关键作用。最新研究表明,在肿瘤发生和治疗过程中,TILs的亚群组成和数量与患者预后密切相关;抗肿瘤的TILs介导的过继性免疫治疗方法已在多种实体瘤中取得了良好的疗效。文中就实体肿瘤中TILs的研究进展作一综述。     

恶性肿瘤组织中结核杆菌DNA的检测

目的　探讨结核杆菌感染与恶性肿瘤的关系。方法　采用多聚酶链反应（ＰＣＲ） 技术检测两种恶性肿瘤组织中结核杆菌ＤＮＡ（ＴＢ－ ＤＮＡ） 。结果４１ 例恶性肿瘤组织中检出ＴＢ－ ＤＮＡ 阳性患者８ 例,占１９．５ ％ ,且ＴＢ－ＤＮＡ 阳性患者肿瘤发病部位基本与结核病的好发部位一致。结论 结核杆菌感染可能与一些恶性肿瘤存在特殊相关性。     

全身麻醉下不同脑电双频指数对老年胃肠道恶性肿瘤患者应激反应、炎性因子和术后认知功能的影响

摘要 目的：观察全身麻醉下不同脑电双频指数（BIS）对老年胃肠道恶性肿瘤患者应激反应、炎性因子和术后认知功能的影响。方法：选择2020年10月-2021年4月在新疆医科大学附属肿瘤医院初诊的住院老年胃肠道恶性肿瘤患者,共98例。据随机数字表法分为浅麻醉组（n=49,BIS值45~55）和深麻醉组（n=49,BIS值30~40）。对比两组苏醒质量、应激反应、炎性因子、术后认知功能、血流动力学及不良反应。结果：浅麻醉组的苏醒时间、定向力恢复时间、气管拔管时间短于深麻醉组（P<0.05）。插管后即刻（T1）~术毕（T5）时间点,两组心率（HR）、平均动脉压（MAP）均下降后升高（P<0.05）。深麻醉组T1~T5时间点HR、MAP高于浅麻醉组（P<0.05）。手术开始2 h（T4）、拔管后60 min（T6）时间点,两组皮质醇（Cor）、促肾上腺皮质激素（ACTH）水平呈升高趋势,且浅麻醉组高于深麻醉组（P<0.05）。T4、T6时间点,两组白介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）水平持续升高,但浅麻醉组低于深麻醉组（P<0.05）。深麻醉组的术后3 d、术后7 d 简明精神状态量表（MMSE）评分低于浅麻醉组（P<0.05）。两组不良反应发生率组间对比无差异（P>0.05）。结论：全身麻醉下老年胃肠道恶性肿瘤患者BIS值范围30~40可维持更平稳的血流动力学,应激反应低,但是其对认知功能影响相对较大;BIS值在45~55之间时,患者苏醒快,炎性因子水平更低;临床应结合实际情况合理调控BIS值。     

替莫唑胺在侵袭性垂体瘤及垂体腺癌中的治疗进展

替莫唑胺(TMZ)是一种口服二代咪唑并四嗪类具有抗肿瘤活性的烷化剂,通过对DNA鸟嘌呤的甲基化来干扰基因转录而诱导DNA损伤,目前是治疗恶性胶质瘤的一线化疗药物.最近有关于TMZ治疗侵袭性垂体腺瘤及垂体癌的报道,有效率分别为60％和69％,且未发生明显并发症.O6-甲基鸟嘌呤-DNA转移酶(MGMT)的表达水平与其疗效呈负相关,从而可能干扰其疗效,由于目前缺乏对垂体癌及侵袭性垂体瘤的有效治疗手段,所以不应否认TMZ对此类患者的治疗有效性.TMZ对侵袭性垂体瘤及垂体癌的治疗机制及有效性仍需进一步探索.     

妇科盆腔恶性肿瘤血常规检测结果分析

目的:了解妇科盆腔恶性肿瘤血常规变化及其临床意义。方法:以无锡市人民医院2018年1月～2019年3月收治的90例妇科盆腔恶性肿瘤患者作为病例组,同期住院的243例确诊为盆腔良性病变或妊娠状态的患者作为良性对照组,选取同期717名接受体检的成年女性作为健康对照组,对三组研究对象的血常规指标进行回顾性分析。结果:与健康对照组比较,良性对照组和病例组患者的嗜酸性粒细胞百分比(EO)、嗜酸性粒细胞计数(EO#)、红细胞压积(HCT)、血红蛋白水平(HGB)、淋巴细胞百分比(LY)、淋巴细胞计数(LY#)、红细胞平均血红蛋白浓度(MCHC)、血小板分布宽度(PDW)、红细胞计数(RBC)水平降低,单核细胞计数(MO#)、血小板平均体积(MPV)、中性粒细胞百分比(NE)、中性粒细胞计数(NE#)、红细胞分布宽度(RDW)、白细胞计数(WBC)水平升高;病例组患者EO、EO#、LY、LY#、MO#、MPV水平低于良性对照组,HCT、HBG、MCHC、PDW、NE、NE#、RDW水平高于良性对照组,同时,病例组患者的红细胞平均血红蛋白含量(MCH)、红细胞平均体积(MCV)水平高于健康对照组,健康对照组的MCH、MCV水平高于良性对照组,良性对照组患者的单核细胞百分比(MO)、血小板压积(PCT)水平高于健康对照组,健康对照组的MO、PCT水平高于病例组,差异均有统计学意义(P0.05)。Logistic多元回归分析结果显示,LY#、MO#、MCHC、RDW、MCH、MCV与盆腔恶性肿瘤的发生具有相关性(P0.05)。ROC曲线分析结果显示,在各项血常规指标中,MCV诊断妇产科盆腔恶性肿瘤的曲线下面积(AUC)最高,为0.683。结论:盆腔恶性肿瘤患者的血常规指标与良性病变患者和健康人群均存在差异,部分指标与恶性肿瘤的发生具有独立相关性。     

Nucleic acid-based vaccine for ovarian cancer cells; bench to bedside

Ovarian cancer continues to be a difficult medical issue that affects millions of individuals worldwide. Important platforms for cancer immunotherapy include checkpoint inhibitors, chimeric antigen receptor T cells, bispecific antibodies, cancer vaccines, and other cell-based treatments. To avoid numerous infectious illnesses, conventional vaccinations based on synthetic peptides, recombinant subunit vaccines, and live attenuated and inactivated pathogens are frequently utilized. Vaccine manufacturing processes, however, are not entirely safe and carry a significant danger of contaminating living microorganisms. As a result, the creation of substitute vaccinations is required for both viral and noninfectious illnesses, including cancer. Recently, there has been testing of nucleic acid vaccines, or NAVs, as a cancer therapeutic. Tumor antigens (TAs) are genetically encoded by DNA and mRNA vaccines, which the host uses to trigger immune responses against ovarian cancer cells that exhibit the TAs. Despite being straightforward, safe, and easy to produce, NAVs are not currently thought to be an ideal replacement for peptide vaccines. Some obstacles to this strategy include selecting the appropriate therapeutic agents (TAs), inadequate immunogenicity, and the immunosuppressive characteristic of ovarian cancer. We focus on strategies that have been employed to increase NAVs' effectiveness in the fight against ovarian cancer in this review.     

Design,synthesis and biological evaluation of coumarin-3-carboxamides as selective carbonic anhydrase IX and XII inhibitors

A series of novel 7-hydroxycoumarin-3-carboxamides was synthesized by the reaction of 7-hydroxy-2-oxo-2H-chromene-3-carboxylic acid with various substituted aromatic amines. The newly synthesized compounds were evaluated for their inhibitory activity against the four physiologically relevant human carbonic anhydrase (hCA, EC 4.2.1.1) isoforms CA I, CA II, CA IX and CA XII. The CA inhibition results show that the newly synthesized 7-hydroxycoumarin-3-carboxamides (4a-n) exhibited selective inhibition of the tumor associated isoforms, CA IX and CA XII over CA I and II isoforms. The inhibition constants ranged from sub micromolar to low micromolar. Amongst all the compounds tested, compound 4m was the most effective inhibitor exhibiting sub micromolar potency against both hCA IX and hCA XII, with a K_i of 0.2 µM. Therefore, it can be anticipated that compound 4m can serve as a lead for development of anticancer therapy by exhibiting a novel mechanism of action. The binding modes of the most potent compounds within hCA IX and XII catalytic clefts were investigated by docking studies.